TUSTIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , will host a conference call and simultaneous webcast on Friday, December 9, 2005. Peregrine’s management will discuss financial results for the second quarter ended October 31, 2005, and will provide an update on the company’s progress. The second quarter results will also be reported in a press release distributed on the morning of December 9th before the market opens.
The conference call and live webcast will begin at 11:00 a.m. ET/ 8:00 a.m. PT. Please call the following number approximately 10 minutes prior to the scheduled time of the call: 1-800-860-2442. A telephonic replay of the conference call will also be available through December 16, 2005, by calling 1-877-344-7529, passcode 382933#.
To listen to a live broadcast of the call over the Internet, please visit: http://www.peregrineinc.com . The broadcast will be archived on Peregrine’s website for 30 days.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin(TM) and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers.
Investors: Brod & Schaffer, LLC Betsy Brod/Jonathan Schaffer ir@peregrineinc.com (800)987-8256
Peregrine Pharmaceuticals, Inc.
CONTACT: Betsy Brod or Jonathan Schaffer, both of Brod & Schaffer, LLC,+1-800-987-8256, ir@peregrineinc.com, for Peregrine Pharmaceuticals, Inc.
